Thermachoice® III

Time

Temperature

Pressure

Make it your choice...



Uterine Balloon Therapy System

ORDERING INFORMATION:

GYNECARE THERMACHOICE® III

GYNECARE THERMACHOICE® III

TO ORDER CALL: **1-800-255-2500**

ESSENTIAL PRODUCT INFORMATION:

INDICATIONS: The GYNECARE THERMACHOICE® UBT System is a thermal balloon ablation device intended to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia (excessive uterine bleeding) due to benign causes for whom childbearing is complete. CONTRAINDICATIONS: The device is contraindicated for use in a patient: who is pregnant or who wants to become pregnant in the future; with known or suspected endometrial carcinoma (uterine cancer) or premalignant change of the endometrium, such as unresolved adenomatous hyperplasia; with any anatomic or pathologic condition in which weakness of the myometrium could exist, such as history of previous classical cesarean sections or transmural myomectomy; with active genital or urinary tract infection at the time of procedure (e.g., cervicitis, vaginitis, endometritis, salpingitis, or cystitis); with an intrauterine device (IUD) currently in place. ADVERSE EVENTS INCLUDE: rupture of the uterus; thermal injury to adjacent tissue; heated liquid escaping into the vascular spaces and/or cervix, vagina, fallopian tubes, and abdominal cavity; electrical burn; hemorrhage; infection or sepsis; perforation; post-ablation-tubal sterilization syndrome; complications leading to serious injury or death; complications with pregnancy (Note: pregnancy following ablation is dangerous to both the mother and the fetus); vesico-uterine fistula formation; cramping/pelvic pain; nausea and vomiting; endometritis and risks associated with hysteroscopy. WARNINGS: Failure to follow all instructions or to heed any warnings or precautions could result in serious patient injury. If uterine perforation is present, and the procedure is not terminated, thermal injury to adjacent tissue may occur if the heater is activated. Endometrial ablation is not a sterilization procedure. Patients who have previously undergone tubal ligation are at increased risk of developing post-ablation-tubal sterilization syndrome which can require hysterectomy. Endometrial ablation procedures using the GYNECARE THERMACHOICE® UBT System should be performed only by medical professionals who have experience in performing procedures within the uterine cavity, such as IUD insertion or dilation and curettage (D&C), and who have adequate training and familiarity with GYNEC-ARE THERMACHOICE® UBT System. PRECAUTIONS: Never use other components with the GYNECARE THERMACHOICE® UBT System. Refer to package insert for complete product information including warnings, precautions, and adverse reactions. RX Only.

THE INFORMATION CONTAINED IN THIS DOCUMENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENTS NO STATEMENT, PROMISE, OR GUARANTEE BY Ethicon Women's Health & Urology CONCERNING LEVELS OF REMBURSEMENT, PAYMENT, OR CHARGE. SIMILARLY, ALL CPT (COPYRIGHT AMA) AND HCPCS CODES ARE SUPPLIED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENT NO STATEMENT, PROMISE, OR GUARANTEE BY Ethicon Women's Health and Urology THAT THESE CODES WILL BE APPROPRIATE OR THAT REIMBURSEMENT WILL BE MADE. IT IS NOT INTENDED TO INCREASE OR MAXIMIZE REIMBURSEMENT BY ANY PAYOR. WE STRONGLY RECOMMEND THAT YOU CONSULT YOUR PAYOR ORGANIZATION WITH REGARD TO ITS REIMBURSEMENT POLICIES.





A division of ETHICON, INC. a Johnson & Johnson company Did you know studies show up to 93%

of Women with menorrhagia suffer from both Bleeding and Pain?^(2,6,7)



Uterine Balloon Therapy System

It's Time For Thermachoice® III

	An Effective Solution To Help Stop Heavy Bleeding.		Reduction In Pain at one year.
Patients report comparisons*	Patients experiencing amenorrhea at 12 months	Patients with normal levels or less	Patients experiencing reduction in dysmenorrhea (Pain)
GYNECARE THERMACHOICE® III(1)	37%	81%	89%
NovaSure ^{®(2)}	36%	78%	63%
Her Option ^{®(3)}	22%	67%	88%(4)
HTA System ^{®(5)}	35%	68%	N/A

*Not based on a head to head clinical study

*Based on intent-to-treat population (1) GYCECARE THERMACHOICE® III. Instructions for use. ©2008 Ethicon, Inc. (2) NovaSure. Instructions for use. ©2004 Cytc Corporation. (3) Her Option. Instructions for use. ©2006 American Medical Systems, Inc. (4) Antoni J. Duleba, M.D., Martha C.Heppard, M.D., Richard M.Soderstrom, M.D.A Randomized Study Comparing Endometrial Cryoablation and Rollerball Electroablation for treatment of Dysfunctional Uterine Bleeding. *The Journal of the American Association of Gynecologic Laparoscopists*.2003;10:17-26 (5) Hydro ThermAblator System. Instructions for use. © 2005 Boston Scientific Corporation. N/A = not available (6) NovaSure. Instructions for use. © 2004 Cyt Corporation. Summary of Safety & Effectiveness Data: GYNECARE THERMACHOICE® Uterine Balloon Therapy System. PMA970021. 1997 (7) Summary of Safety & Effectiveness Data: CryoGen Her Option Uterine Cryoablation Therapy System. PMA P000032, version 8.0. September 14, 2002

Make **GYNECARE THERMACHOICE® III** your choice... for customized coverage...to help end heavy periods.

89% OF PATIENTS in a study had a reduction in menstral PAIN AND CRAMPING.(1)

(1) GYCECARE THERMACHOICE® III, IFU, ETHICON, Inc.









Conforms to most uterine shapes and sizes with no reduction of efficacy

Delivers more even necrosis of tissue throughout the entire endometrium (Based on ex vivo studies versus previous balloon)

Requires minimal dilation for greater patient safety and comfort